AndreaWang-GillamMD

Oncology • Creve Coeur, MO

Gastrointestinal Cancer, Hematologic Oncology

Associate Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Wang-Gillam is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wang-Gillam's full profile

Already have an account?

Office
10 Barnes West Dr
Creve Coeur, MO 63141
Phone+1 314-747-1171

Fax+1 314-362-3646
Is this information wrong?

Education & Training

University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2002 - 2004
Cleveland Clinic FoundationInternship, Internal Medicine, 2001 - 2002
University of Arkansas For Medical Sciences College of MedicineClass of 2001

Certifications & Licensure

MO State Medical License 2007 - 2025
AR State Medical License 2003 - 2009
OH State Medical License 2001 - 2003

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Start of enrollment: 2011 May 10
Active, not recruiting
Phase 1
Registry Study - Whipple at the Splenic Artery Start of enrollment: 2010 Sep 20
Completed
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Start of enrollment: 2012 Apr 01
Completed
Phase 1
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma Start of enrollment: 2009 Dec 16
Completed
Phase 1
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Start of enrollment: 2013 May 07
Completed
Phase 1
Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies Start of enrollment: 2013 Oct 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer Start of enrollment: 2013 Nov 08
Completed
Phase 2
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Completed
Phase 2
Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery Start of enrollment: 2014 Jun 01
Terminated
Phase 1
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors Start of enrollment: 2018 Sep 11
Terminated
Phase 1
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy Start of enrollment: 2019 Jul 11
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer.
Ashenafi Bulle, Peng Liu, Kuljeet Seehra, Sapana Bansod, Yali Chen, Kiran Zahra, Vikas Somani, Iftikhar Ali Khawar, Hung-Po Chen, Paarth B Dodhiawala, Lin Li, Yutong G...> ;Nature Communications. 2024 Mar 20
Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505.
Boutin, R., Kim, J., Beg, M., Wade, J., Guthrie, K., Chiorean, E., Ahmad, S., Lowy, A., Sohal, D., Lenchik, L., Wang-Gillam, A., Philip, P., Chang, V.> ;Journal of Gastrointestinal Surgery. 2024 Mar 1
Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.
Max M Wattenberg, Sarah Colby, Ignacio Garrido-Laguna, Yuqing Xue, Renee Chang, Devora Delman, Jesse Lee, Kajsa Affolter, Sean J Mulvihill, M Shaalan Beg, Andrea Wang-...> ;Gastroenterology. 2024 Jan 18
(HER2) amplifications and co-occurringalterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition.
Weipert, C., Espenschied, C., Raymond, V., Gordon, E., Barzi, A., Wang-Gillam, A., Nezami, M., Mahadevan, D., Mody, K.> ;Frontiers in Oncology. 2024 Jan 1
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
Patrick M Grierson, Rama Suresh, Benjamin Tan, Katrina S Pedersen, Manik Amin, Haeseong Park, Nikolaos A Trikalinos, Jingxia Liu, Nicholas Boice, Amberly Brown, Sapana...> ;Clinical Cancer Research. 2023 Dec 1
2 citations
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States.
Andrea Wang-Gillam, William Schelman, Stacey Ukrainskyj, Caly Chien, Martha Gonzalez, Zhao Yang, Marek Kania, Heather Yeckes-Rodin> ;Investigational New Drugs. 2023 Dec 1
1 citations
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with adv...
Rom Leidner, Kevin Conlon, Douglas G McNeel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessic...> ;Journal for Immunotherapy of Cancer. 2023 Oct 1
Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration.
Gregory L Beatty, Devora Delman, Jiayi Yu, Mingen Liu, Joey H Li, Liti Zhang, Jae W Lee, Renee B Chang, Nathan Bahary, Eugene P Kennedy, Andrea Wang-Gillam, Gabriela R...> ;Clinical Cancer Research. 2023 Sep 1
8 citations
Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma.
Patrick M Grierson, Benjamin Tan, Katrina S Pedersen, Haeseong Park, Rama Suresh, Manik A Amin, Nikolaos A Trikalinos, Deborah Knoerzer, Brent Kreider, Anupama Reddy, ...> ;The Oncologist. 2023 Feb 8
4 citations
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarc...
Brandon M Huffman, Atrayee Basu Mallick, Nora K Horick, Andrea Wang-Gillam, Peter Joel Hosein, Michael A Morse, Muhammad Shaalan Beg, Janet E Murphy, Sharon Mavroukaki...> ;JAMA Network Open. 2023 Jan 3
3 citations
MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial.
Hyun Kim, Jeffrey R Olsen, Olga L Green, Re-I Chin, William G Hawkins, Ryan C Fields, Chet Hammill, Majella B Doyle, William Chapman, Rama Suresh, Benjamin Tan, Katrin...> ;International Journal of Radiation Oncology, Biology, Physics. 2023 Jan 1
22 citations
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C Lockhart, Amberly Brown, Marcus Breden, Jad I Belle, John Herndon, Savannah J Bogner, Katri...> ;Clinical Cancer Research. 2022 Dec 15
4 citations
A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond.
Marcus S Noel, Semmie Kim, Marion L Hartley, Steve Wong, Vincent J Picozzi, Harry Staszewski, Dae Won Kim, Jan M Van Tornout, Philip Agop Philip, Vincent Chung, Allyso...> ;Cancer Medicine. 2022 Nov 1
4 citations
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
Nusayba A Bagegni, Haeseong Park, Katlyn Kraft, Maura O-Toole, Feng Gao, Saiama N Waqar, Lee Ratner, Daniel Morgensztern, Siddhartha Devarakonda, Manik Amin, Maria Q B...> ;Cancer Chemotherapy and Pharmacology. 2022 Apr 1
1 citations
Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment.
Hua Sun, Song Cao, R Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C Wendl, Sherri R Davies, Matthew H Bailey, Tina M Primeau, Jeremy Hoog, Jacqueline L Mudd, Denn...> ;Nature Communications. 2022 Jan 7
32 citations
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.
Mark Yarchoan, Leslie Cope, Amanda N Ruggieri, Robert A Anders, Anne M Noonan, Laura W Goff, Lipika Goyal, Jill Lacy, Daneng Li, Anuj K Patel, Aiwu R He, Ghassan K Abo...> ;The Journal of Clinical Investigation. 2021 Dec 15
10 citations
Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Catrcinoma by Inhibiting IL-6 Signaling Pathway
Yao Lu, Dao Xin, Lulu Guan, Mengli Xu, Yalan Yang, Yu Chen, Yuanyuan Yang, Andrea Wang-Gillam, Li Wang, Shanggang Zong, Feng Wang> ;Frontiers in Oncology. 2021 Nov 22
22 citations
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
Kevin C. Conlon, Dionysios C. Watson, Thomas A. Waldmann, Antonio Valentin, Cristina Bergamaschi, Barbara K. Felber, Cody J. Peer, William D. Figg, E. Lake Potter, Mar...> ;Journal for Immunotherapy of Cancer. 2021 Nov 1
12 citations
Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies.
Andrew Eugene Hendifar, Edik M. Blais, Brian M. Wolpin, Vivek Subbiah, Eric A. Collisson, Isha Singh, Timothy Cannon, Kenna R. Mills Shaw, Emanuel F. Petricoin, Samuel...> ;JCO Precision Oncology. 2021 Aug 25
48 citations
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
Hua Sun, Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl, Sherri R. Davies, Matthew H. Bailey, Tina Primeau, Jeremy Hoog, Jacqueline Mudd, Denn...> ;Nature Communications. 2021 Aug 24
4 citations
Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
Manik Amin, Feng Gao, Gretel Terrero, Joel Picus, Andrea Wang-Gillam, Rama Suresh, Cynthia Ma, Benjamin R. Tan, Maria Q. Baggstrom, Michael J. Naughton, Lauren Trull, ...> ;American Journal of Clinical Oncology. 2021 Sep 1
5 citations
Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies.
Kian-Huat Lim, Mateusz Opyrchal, Abhi Acharya, Nick Boice, Ningying Wu, Feng Gao, Jace Webster, Albert C. Lockhart, Saiama N. Waqar, Ramaswamy Govindan, Daniel Morgens...> ;European Journal of Cancer. 2021 Jul 10
15 citations
Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial.
Hyun Jik Kim, Katrina S. Pedersen, Jeffrey R. Olsen, Matthew G. Mutch, R.I. Chin, Sean C. Glasgow, Paul E. Wise, Matthew L. Silviera, Benjamin R. Tan, Andrea Wang-Gill...> ;Clinical Colorectal Cancer. 2021 Apr 7
14 citations
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
Katrina S. Pedersen, Patrick M. Grierson, Joel Picus, A. Craig Lockhart, Bruce J. Roth, Jingxia Liu, Ashley Morton, Emily Chan, Jesse Huffman, Chris Liang, Andrea Wang...> ;Investigational New Drugs. 2021 Mar 18
131 citations
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Davendra Sohal, Mai Duong, Syed A. Ahmad, Namita S. Gandhi, M. Shaalan Beg, Andrea Wang-Gillam, James L. Wade, E. Gabriela Chiorean, Katherine A. Guthrie, Andrew M. Lo...> ;JAMA Oncology. 2021 Mar 1
Join now to see all

Journal Articles

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma
Andrea Wang-Gillam, Howard S Hochster, JAMA Oncology
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers
Haeseong Park, Andrea Wang-Gillam, Caron Rigden, Katrina S Pedersen, Nikolaos A Trikalinos, JAMA Oncology

Lectures

Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

FOLFIRINOX for the Treatment of Advanced Gastroesophageal CancersMay 2020

Press Mentions

Verastem Oncology Reports Second Quarter 2018 Financial ResultsAugust 8th, 2018
Verastem Oncology Presents Data on Two Lead Drug Candidates at ASCO 2018 Annual MeetingJune 4th, 2018
Defactinib Combined with Pembrolizumab and Gemcitabine in Patients with Advanced CancerApril 18th, 2016
Join now to see all